{"id":38209,"date":"2025-07-30T14:41:55","date_gmt":"2025-07-30T06:41:55","guid":{"rendered":"https:\/\/flcube.com\/?p=38209"},"modified":"2025-07-30T14:41:56","modified_gmt":"2025-07-30T06:41:56","slug":"eli-lillys-jaypirca-achieves-primary-endpoint-in-phase-iii-bruin-cll-314-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38209","title":{"rendered":"Eli Lilly&#8217;s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial"},"content":{"rendered":"\n<p>US pharmaceutical giant Eli Lilly &amp; Co. (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced on July 29, 2025, that its non-covalent, reversible BTK inhibitor, Jaypirca (pirtobrutinib), achieved its primary endpoint in the Phase III BRUIN CLL-314 head-to-head study for the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). This marks the first Phase III trial directly comparing a non-covalent BTK inhibitor with a covalent BTK inhibitor, Imbruvica (ibrutinib), in treatment-na\u00efve patients.<\/p>\n\n\n\n<p><strong>Clinical Trial Design and Results<\/strong><br>The BRUIN CLL-314 trial enrolled 650 patients with CLL\/SLL, including those who were treatment-na\u00efve or had previously been treated but not with a BTK inhibitor. Patients were randomized 1:1 to receive either pirtobrutinib (200mg once daily) or ibrutinib (420mg once daily). The primary endpoint was Overall Response Rate (ORR) as assessed by a Blinded Independent Review Committee (IRC). The study demonstrated that pirtobrutinib was non-inferior to ibrutinib in terms of ORR and showed a statistical advantage. A pronounced trend in progression-free survival (PFS) was observed among treatment-na\u00efve patients (n=225), although PFS data are still immature. The results favored pirtobrutinib, and no adverse impact on overall survival (OS) was observed. The safety profile of pirtobrutinib was consistent with previous studies, with no new serious adverse reactions identified.<\/p>\n\n\n\n<p><strong>Significance and Future Steps<\/strong><br>These results follow the success of the BRUIN CLL-321 study and, together with ongoing data from the BRUIN CLL-313 study, will support global regulatory submissions for pirtobrutinib. Jaypirca is currently approved in the U.S. for CLL\/SLL patients who have previously received both a BTK inhibitor and a BCL-2 inhibitor. Full data from the BRUIN CLL-314 trial will be presented at a medical conference later in 2025.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US pharmaceutical giant Eli Lilly &amp; Co. (NYSE: LLY) announced on July 29, 2025, that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38211,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,17,199,911],"class_list":["post-38209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-results","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly&#039;s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical giant Eli Lilly &amp; Co. (NYSE: LLY) announced on July 29, 2025, that its non-covalent, reversible BTK inhibitor, Jaypirca (pirtobrutinib), achieved its primary endpoint in the Phase III BRUIN CLL-314 head-to-head study for the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). This marks the first Phase III trial directly comparing a non-covalent BTK inhibitor with a covalent BTK inhibitor, Imbruvica (ibrutinib), in treatment-na\u00efve patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38209\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly&#039;s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial\" \/>\n<meta property=\"og:description\" content=\"US pharmaceutical giant Eli Lilly &amp; Co. (NYSE: LLY) announced on July 29, 2025, that its non-covalent, reversible BTK inhibitor, Jaypirca (pirtobrutinib), achieved its primary endpoint in the Phase III BRUIN CLL-314 head-to-head study for the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). This marks the first Phase III trial directly comparing a non-covalent BTK inhibitor with a covalent BTK inhibitor, Imbruvica (ibrutinib), in treatment-na\u00efve patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38209\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T06:41:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-30T06:41:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3008.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly&#8217;s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial\",\"datePublished\":\"2025-07-30T06:41:55+00:00\",\"dateModified\":\"2025-07-30T06:41:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209\"},\"wordCount\":288,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3008.webp\",\"keywords\":[\"Cancer\",\"Clinical trial results\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38209#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38209\",\"name\":\"Eli Lilly's Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3008.webp\",\"datePublished\":\"2025-07-30T06:41:55+00:00\",\"dateModified\":\"2025-07-30T06:41:56+00:00\",\"description\":\"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that its non-covalent, reversible BTK inhibitor, Jaypirca (pirtobrutinib), achieved its primary endpoint in the Phase III BRUIN CLL-314 head-to-head study for the treatment of chronic lymphocytic leukemia\\\/small lymphocytic lymphoma (CLL\\\/SLL). This marks the first Phase III trial directly comparing a non-covalent BTK inhibitor with a covalent BTK inhibitor, Imbruvica (ibrutinib), in treatment-na\u00efve patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38209\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3008.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3008.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly's Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38209#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly&#8217;s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial - Insight, China&#039;s Pharmaceutical Industry","description":"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that its non-covalent, reversible BTK inhibitor, Jaypirca (pirtobrutinib), achieved its primary endpoint in the Phase III BRUIN CLL-314 head-to-head study for the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). This marks the first Phase III trial directly comparing a non-covalent BTK inhibitor with a covalent BTK inhibitor, Imbruvica (ibrutinib), in treatment-na\u00efve patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38209","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial","og_description":"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that its non-covalent, reversible BTK inhibitor, Jaypirca (pirtobrutinib), achieved its primary endpoint in the Phase III BRUIN CLL-314 head-to-head study for the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). This marks the first Phase III trial directly comparing a non-covalent BTK inhibitor with a covalent BTK inhibitor, Imbruvica (ibrutinib), in treatment-na\u00efve patients.","og_url":"https:\/\/flcube.com\/?p=38209","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-30T06:41:55+00:00","article_modified_time":"2025-07-30T06:41:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3008.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38209#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38209"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly&#8217;s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial","datePublished":"2025-07-30T06:41:55+00:00","dateModified":"2025-07-30T06:41:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38209"},"wordCount":288,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38209#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3008.webp","keywords":["Cancer","Clinical trial results","Eli Lilly","NYSE: LLY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38209#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38209","url":"https:\/\/flcube.com\/?p=38209","name":"Eli Lilly's Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38209#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38209#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3008.webp","datePublished":"2025-07-30T06:41:55+00:00","dateModified":"2025-07-30T06:41:56+00:00","description":"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that its non-covalent, reversible BTK inhibitor, Jaypirca (pirtobrutinib), achieved its primary endpoint in the Phase III BRUIN CLL-314 head-to-head study for the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). This marks the first Phase III trial directly comparing a non-covalent BTK inhibitor with a covalent BTK inhibitor, Imbruvica (ibrutinib), in treatment-na\u00efve patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38209#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38209"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38209#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3008.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3008.webp","width":1080,"height":608,"caption":"Eli Lilly's Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38209#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly&#8217;s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3008.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38209"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38209\/revisions"}],"predecessor-version":[{"id":38212,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38209\/revisions\/38212"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38211"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}